NCT04187703View on ClinicalTrials.gov

5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 16, 2020

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2026

Conditions
Myelodysplastic SyndromesMDS/MPN Crossover Syndromes
Interventions
DRUG

5-azacytidine

5-azacytidine 50 mg/m\^2 Day 1 every week ± G-CSF \~5 µg/kg (300µg vs 480µg)

DRUG

Decitabine

Decitabine 5 mg/m\^2 Day 4 every week ± G-CSF \~5 µg/kg (300µg vs 480µg)

Trial Locations (1)

44106

RECRUITING

Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Benjamin Tomlinson

OTHER